Notice of Intent to Publish a Funding Opportunity Announcement for Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional)
ID: 354361Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354361
Timeline
    Description

    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement (FOA) for addressing barriers to healthcare transitions for survivors of childhood and adolescent cancers. This FOA aims to support multi-level intervention studies that address individual and system level barriers to transitions from pediatric to adult care for these survivors. The goal is to develop and test interventions and strategies that promote high-quality transitional care and continued engagement of survivors to ensure appropriate surveillance and care into adulthood. The anticipated outcome of this research is to establish best practices and standards of care that can be widely disseminated and adopted. The FOA is associated with the STAR Reauthorization Act of 2023, which focuses on maximizing and accelerating the availability of promising models of care for pediatric cancer survivors. The FOA is expected to be published in June 2024, with an application due date in October 2024. It will utilize the R01 activity code.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity aimed at improving care and outcomes for cancer survivors from sexual and gender minority (SGM) populations. This initiative seeks proposals for observational and interventional studies that assess barriers to quality cancer treatment and follow-up care for SGM individuals, utilizing interoperable sexual orientation and gender identity (SOGI) data collection methods. The funding is crucial for addressing healthcare disparities faced by SGM cancer survivors and aims to foster culturally sensitive care and effective interventions. Applications are due starting January 5, 2024, with funding available for up to five years, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)" aimed at supporting collaborative research projects that address the long-term adverse effects of cancer therapies. The initiative seeks to identify and characterize the mechanisms behind therapy-induced adverse sequelae, with a focus on developing therapeutic strategies to prevent or mitigate these chronic comorbidities. This funding opportunity is crucial for enhancing patient quality of life through effective interventions based on mechanistic insights and clinical findings. Interested applicants, including various educational and community organizations, must submit their proposals by November 5, 2024, and can find additional information at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Paul Calabresi Career Development Award for Clinical Oncology (K12), aimed at supporting institutional research career development programs for clinical scientists in cancer research. This initiative emphasizes training for clinical scientists who aspire to lead independent clinical trials or contribute to existing trials, thereby enhancing the field of clinical cancer research. The NOFO is anticipated to be released in November 2024, with the first application deadline set for February 2025, and the estimated award date is January 5, 2026. Interested applicants are encouraged to begin developing collaborations and applications in advance, as there are no cost-sharing requirements associated with this grant opportunity.
    Notice of Intent to Publish a Notice of Funding Opportunity for Social Determinants of Health (SDoH) and Quality of Care Contributors to Cancer Disparities in People with HIV (U01; Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at understanding the impact of social determinants of health (SDoH) on cancer disparities among people with HIV (PWH). This initiative seeks applications for research that explores health disparities throughout the cancer care continuum, including aspects such as screening, diagnosis, treatment, quality of life, and survivorship, with the goal of enhancing the NIH's research portfolio in this critical area. The funding opportunity, which will utilize the U01 cooperative agreement mechanism, anticipates awarding approximately four grants with a ceiling of $500,000 each, contributing to an estimated total program funding of $3 million. Interested applicants should prepare for the expected publication of the NOFO in fall 2024, with application deadlines projected for winter 2025, 2026, and 2027, and an anticipated award date of July 1, 2025.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at researching the intersection of cancer stigma and HIV stigma in individuals diagnosed with both conditions. This initiative seeks to advance understanding of how these stigmas affect cancer outcomes among HIV-positive individuals, promote stigma reduction interventions, and encourage research in areas with high HIV-cancer burdens. The NIH plans to award up to six R01 grants, each with a ceiling of $500,000, as part of a total estimated funding pool of $5 million, with the NOFO expected to be published in late Summer 2024 and applications due in late Fall 2024. Interested applicants are encouraged to prepare by reviewing related presentations and materials available online.
    Notice of Intent to Publish a Funding Opportunity Announcement for Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) initiative, specifically targeting Tobacco Use Treatment for Cancer Survivors. This initiative aims to fund up to three research projects that will develop and test strategies to enhance the delivery and sustainability of tobacco use treatment services for cancer survivors, utilizing the UG3/UH3 Exploratory/Developmental Cooperative Agreement activity code, which requires clinical trials. The total estimated funding for this opportunity is $2.4 million, with applications expected to be due in late Fall 2024 and awards anticipated by July 1, 2025. Interested applicants are encouraged to prepare by reviewing related materials and attending a pre-application webinar, details of which will be announced following the NOFO publication.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network (NCTN) - Network Group Operations Centers, which will require a U10 clinical trial. This initiative aims to provide scientific leadership for the development and implementation of multi-disciplinary, multi-institutional clinical trials targeting various cancer types and populations, focusing on late-phase treatment trials and advanced imaging studies. The funding, estimated at $99.3 million, is intended to support the conduct of essential clinical research for adults, adolescents, and children with cancer, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, applicants should prepare their submissions in advance of the anticipated award date of March 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for The confluence of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at exploring the intersection of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer. This initiative seeks to support pilot and exploratory research that enhances understanding of how these dual stigmas affect cancer outcomes and promotes research in both domestic and international contexts, particularly in regions with a high burden of HIV and cancer. The NIH anticipates funding up to three R21 grants, with a total estimated funding of $1,000,000, and the NOFO is expected to be published in late Summer 2024, with applications due in late Fall 2024. Interested applicants are encouraged to prepare by reviewing the initiative's presentation and will find further details on the application process following the NOFO publication.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.